Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib + Docetaxel in Platinum-Refractory Ovarian Cancer
NCT00216112Phase 2Completed
- Start
- Dec 2003
- Primary completion
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in ovarian cancer, primary peritoneal carcinoma (PPC) and fallopian tube cancer (PFTC). Primary endpoint: Response Rate (CR, PR and SD) at 24 months. Started Dec 2003; status: completed.
02
Drugs
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00216112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00216112.